Public Profile
- Chief, Division of Endocrinology
- Director, Diabetes Center
- NC Translational and Clinical Sciences Institute
- University of North Carolina School of Medicine
Affiliations
University of North Carolina School of Medicine; the American Diabetes Association
DisclosuresDr. Buse says, "My employer, the University of North Carolina, has contracted with a variety of companies since
2005 for my services as an investigator, consultant and/or speaker. These are managed by the
Divisional Administrator who makes all decisions about what work I do for what companies and
controls accounts into which receipts are deposited. These funds do benefit the Division. They
do not provide direct benefit to me, but certainly do so indirectly. These companies include
Amylin, Bayhill Therapeutics, BD Research Laboratories, Bristol-Myers Squibb, Dexcom, Eli
Lilly, GlaxoSmithKline, Hoffman-La Roche, Intekrin, Intuity Medical, Johnson & Johnson,
MannKind, Medtronic, Merck, MicroIslet, Novartis, Novo Nordisk, Osiris, Pfizer, sanofi-aventis,
Transition Therapeutics, and Wyeth."
Dr. John Buse received his medical degree and PhD from Duke University in Durham, North Carolina, before training in internal medicine and endocrinology at the University of Chicago. He is currently a professor at the University of North Carolina School of Medicine in Chapel Hill, North Carolina where he serves as the director of the Diabetes Care Center, chief of the division of endocrinology and executive associate dean for clinical research. Dr. Buse has a diabetes practice located at UNC as well as at the Salem Center in Winston-Salem, North Carolina. His research interests focus on developing prevention and treatment strategies for type 1 diabetes, type 2 diabetes and their complications. He has authored more than 200 publications and is involved in numerous multicenter clinical trials, most prominently the National Heart Lung and Blood Institute’s ACCORD (Action to Control CardiOvascular Risk in Diabetes) study for which he serves as study vice-chair and the National Institute for Diabetes Digestive and Kidney Disease’s STOPP-T2D (Studies to Treat Or Prevent Pediatric Type 2 Diabetes) study. He serves on the Data Safety Monitoring Board or Steering Committee for NIH and international studies such as NAVIGATOR, ORIGIN, IRIS, TECOS, FREEDOM and NASH CRN. Dr. Buse is active in a number of national teaching efforts focusing on graduate medical education as well as CME. Dr Buse just completed service as president for medicine and science at the American Diabetes Association and a board member of the Carolinas Affiliate of the American Association of Clinical Endocrinologists. He has received numerous awards and honors, including citation in Best Doctors in America since 2001.